{
  "id": "PK_CYP1A2_INHIB_TIZANIDINE",
  "name": "CYP1A2 inhibition can markedly increase tizanidine exposure",
  "domain": "PK",
  "severity": "major",
  "rule_class": "adjust_monitor",
  "tags": ["exposure_increase", "sedation_risk", "hypotension_risk"],
  "scenario": {
    "classification": "reference",
    "index_drug": "tizanidine",
    "confidence": "high",
    "notes": "Reference scenario: CYP1A2 inhibitor with tizanidine (CYP1A2 substrate)."
  },
  "actions": [
    "Avoid the combination when possible; consider alternatives.",
    "If used, use reduced tizanidine dosing and close monitoring for hypotension and sedation (educational)."
  ],
  "logic": {
    "enzyme": {
      "id": "CYP1A2",
      "A_role": "substrate",
      "B_role": "inhibitor"
    },
    "A_name_is": "tizanidine",
    "rationale": [
      "{B_name} inhibits CYP1A2, reducing metabolism of tizanidine.",
      "Reduced clearance may increase tizanidine exposure and adverse effects."
    ]
  },
  "explanation_template": "{B_name} inhibits CYP1A2 and tizanidine is a CYP1A2 substrate. This may increase tizanidine exposure, raising risk of sedation and hypotension.",
  "references": [
    {
      "source": "Educational note",
      "citation": "CYP1A2 inhibition can substantially increase exposure of sensitive CYP1A2 substrates such as tizanidine."
    }
  ]
}
